Ajoene and 5-fluorouracil in the topical treatment ofCladophialophoracarrioniichromoblastomycosis in humans: a comparative open study

Open Access
Publisher Website
Google Scholar
Abstract
Ajoene and 5-fluorouracil (5-FU) are compounds that have shown in-vitro activity against Cladophialophoracarrionii, an important etiologic agent of chromoblastomycosis. An open comparative trial was conducted to assess safety and effectiveness of topical ajoene and 5-FU in the treatment of localized chromoblastomycosis. Thirty-seven patients with a clinically and mycologically confirmed diagnosis were randomly distributed into two groups allocated to ajoene (0.5% gel; n=19) or 5-FU (1% cream; n=18). Topical treatment was applied to localized lesions (≤2.5-cm diameter) once a day, with occlusion, for 12–16 weeks. Complete clinical and mycological remission was achieved in 14/19 patients (74%) treated with ajoene and 14/18 patients (78%) treated with 5-FU. All 5-FU-treated patients developed a post-treatment scar at the site of the lesion, while ajoene-treated patients showed only a slight depigmentation of the skin. The differences observed in cure rate between ajoene and 5-FU are not statistically significant. Follow-up of all patients for 4 years revealed no relapses in the ajoene-treated group, while one patient in the 5-FU-treated group had a relapse 6 months after the end of therapy. This trial represents the first clinical use of ajoene in the control of a deep mycosis.